Karolinska Development AB (KDEVF)
0.2576
0.00 (0.00%)
USD |
OTCM |
May 28, 16:00
Karolinska Development Revenue (Quarterly): 0.0454M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.0454M |
| December 31, 2023 | 0.0502M |
| September 30, 2023 | 0.0382M |
| June 30, 2023 | 0.0496M |
| March 31, 2023 | 0.0526M |
| December 31, 2022 | 0.0526M |
| September 30, 2022 | 0.0503M |
| June 30, 2022 | 0.0635M |
| March 31, 2022 | 0.0633M |
| December 31, 2021 | 0.0531M |
| September 30, 2021 | 0.0575M |
| June 30, 2021 | 0.0684M |
| March 31, 2021 | 0.0751M |
| December 31, 2020 | 0.0614M |
| September 30, 2020 | 0.0486M |
| June 30, 2020 | 0.0609M |
| March 31, 2020 | 0.1148M |
| December 31, 2019 | 0.0758M |
| September 30, 2019 | 0.0744M |
| June 30, 2019 | 0.11M |
| March 31, 2019 | 0.0987M |
| December 31, 2018 | 0.0943M |
| September 30, 2018 | 0.0814M |
| June 30, 2018 | 0.0876M |
| March 31, 2018 | 0.0906M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.0903M |
| September 30, 2017 | 0.0661M |
| June 30, 2017 | 0.0636M |
| March 31, 2017 | 0.069M |
| December 31, 2016 | 0.4104M |
| September 30, 2016 | 0.0511M |
| June 30, 2016 | 0.0739M |
| March 31, 2016 | 0.072M |
| December 31, 2015 | 0.0598M |
| September 30, 2015 | 0.0382M |
| June 30, 2015 | 0.1328M |
| March 31, 2015 | 0.1193M |
| December 31, 2014 | 0.2127M |
| September 30, 2014 | 0.1575M |
| June 30, 2014 | 0.1678M |
| March 31, 2014 | 0.1933M |
| December 31, 2013 | 0.1452M |
| September 30, 2013 | 0.2395M |
| June 30, 2013 | 0.1807M |
| March 31, 2013 | 0.1946M |
| December 31, 2012 | 0.3868M |
| September 30, 2012 | 0.2702M |
| June 30, 2012 | 0.4431M |
| March 31, 2012 | 0.3668M |
| December 31, 2011 | 0.4987M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0382M
Minimum
Sep 2023
0.1148M
Maximum
Mar 2020
0.0633M
Average
0.0592M
Median
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Calliditas Therapeutics AB | 28.49M |
| Oncopeptides AB | 0.26M |
| Olink Holding AB | 28.75M |
| BioInvent International AB | 0.5729M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.0201M |
| Total Expenses (Quarterly) | 0.8479M |
| EPS Diluted (Quarterly) | 0.0001 |
| Enterprise Value | 62.17M |
| Profit Margin (Quarterly) | 44.16% |
| Earnings Yield | 4.43% |
| Normalized Earnings Yield | -3.061 |